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A B S T R A C T
Background
It has been estimated that arthritis occurs in 5-7% of those with psoriasis. Relatively few clinical trials of treatment are available for
psoriatic arthritis and data presentation in these trials is far from uniform making comparison difficult.
Objectives
To assess the effects of sulfasalazine, auranofin, etretinate, fumaric acid, IMI gold, azathioprine, efamol marine and methotrexate, in
psoriatic arthritis.
Search methods
We searched MEDLINE up to February 2000, and Excerpta Medica (June 1974-95). Search terms were psoriasis, arthritis, therapy
and/or controlled trial. This was supplemented by manually searching bibliographies of previously published reviews, conference
proceedings, contacting drug companies and referring to the Cochrane Clinical Trials Register. All languages were included in the initial
search.
Selection criteria
All randomized trials comparing sulfasalazine, auranofin, etretinate, fumaric acid, IMI gold, azathioprine, and methotrexate, in psoriatic
arthritis.
Following a published a priori protocol, the main outcome measures included individual component variables derived from Outcome
Measures in Rheumatology Clinical Trials (OMERACT). These include acute phase reactants, disability, pain, patient global assessment,
physician global assessment, swollen joint count, tender joint count and radiographic changes of joints in any trial of one year or longer
[Tugwell 1993], and the change in pooled disease index (DI).
Only English trials were included in the review.
Data collection and analysis
Data were independently extracted from the published reports by two of the reviewers (MC, GJ). An independent blinded quality
assessment was also performed.
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Main results
Twenty randomized trials were identified of which thirteen were included in the quantitative analysis with data from 1022 subjects.
Although all agents were better than placebo, parenteral high dose methotrexate (not included), sulfasalazine, azathioprine and etretinate
were the agents that achieved statistical significance in a global index of disease activity (although it should be noted that only one
component variable was available for azathioprine and only one trial was available for etretinate suggesting some caution is necessary
in interpreting these results). Analysis of response in individual disease activity markers was more variable with considerable differences
between different medications and responses. In all trials the placebo group improved over baseline (pooled improvement 0.39 DI
units, 95% CI 0.26-0.54). There was insufficient data to examine toxicity.
Authors’ conclusions
Parenteral high dose methotrexate and sulfasalazine are the only two agents with well demonstrated published efficacy in psoriatic
arthritis. The magnitude of the effect seen with azathioprine, etretinate, oral low dose methotrexate and perhaps colchicine suggests
that they may be effective but that further multicentre clinical trials are required to establish their efficacy. Furthermore, the magnitude
of the improvement observed in the placebo group strongly suggests that uncontrolled trials should not be used to guide management
decisions in this condition.
P L A I N L A N G U A G E S U M M A R Y
Interventions for treating psoriatic arthritis
It has been estimated that arthritis occurs in 5-7 % of those with psoriasis, which can cause substantial disability in some patients.
The objective was to assess the benefits of the treatment [sulfasalazine, auranofin, etretinate, fumaric acid, IMI gold, azathioprine,
methotrexate] for psoriatic arthritis and to assess the side effects. Parenteral methotrexate and sulfasalazine resulted in important benefit
in over half the patients for psoriatic arthritis in these studies. There was insufficient data to evaluate other therapies and to examine
toxicity. Further multicentre trials are required to establish the efficacy of azathioprine, oral methotrexate, etretinate, and colchicine.
B A C K G R O U N D
It has been estimated that arthritis occurs in 5-7% of those
with psoriasis (Wright 1976). However, this figure becomes much
higher in those who are hospitalized with psoriasis (Leonard 1978).
Certainly, psoriatic arthritis is commonly encountered by rheuma-
tologists and can, on occasion, be difficult to manage. Its overall
natural history appears somewhat better than rheumatoid arthri-
tis (Roberts 1976) although not all agree with this optimism
(Gladman 1990). Relatively few clinical trials of treatment are
available for this condition and data presentation in these trials
is far from uniform making comparison difficult. Often manage-
ment is extrapolated from trials in rheumatoid arthritis but there
is some evidence in the literature to suggest that this may not be
appropriate (Dorwart 1978).
O B J E C T I V E S
In this study we used the technique of meta-analysis to attempt to
answer the following question: How do various treatments com-
pare in terms of both efficacy and toxicity in the treatment of pso-
riatic arthritis?
M E T H O D S
Criteria for considering studies for this review
Types of studies
Following a published a priori protocol the following criteria was
considered.
For inclusion in the meta-analysis, studies had to have at least
two treatment groups, and the allocation to these must have been
by formal randomization. Only articles published in English were
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included due to the necessity of full text evaluation for quality
assessment.
Types of participants
Trials were included of patients aged 20 years and over, with a
clinical diagnosis of psoriatic arthritis.
Types of interventions
All conservative therapeutic agents were eligible for inclusion in
this review. Comparative trials without a placebo arm were not
included. Trials which were placebo-controlled and which also
involved the comparison of two different agents were included.
Types of outcome measures
The main outcome measures included individual component vari-
ables derived from Outcome Measures in Rheumatology Clinical
Trials (OMERACT). These include acute phase reactants, disabil-
ity, pain, patient global assessment, physician global assessment,
swollen joint count, tender joint count and radiographic changes
of joints in any trial of 1 year or longer (Tugwell 1993), and the
change in pooled disease index.
Search methods for identification of studies
A computerized literature search was conducted in May 1994
and updated regularly until February 2000. Data bases used were
MEDLINE (1966-2000) and Excerpta Medica (June 1974-95).
Search terms were psoriasis, arthritis, therapy and/or controlled
trial. The search strategy was supplemented by manually searching
bibliographies of previously published reviews and papers as well as
the conference proceedings of the American College Rheumatol-
ogy Association and the Cochrane Clinical Trials Register. There
was no language restriction in the initial search. We also contacted
drug companies who might be involved in clinical trials.
Data collection and analysis
Data Extraction
Data were independently extracted from the published reports by
two of the authors (MC, GJ). Updated reports were done by one
author only (GJ). Disagreements were resolved by discussion. For
each trial we documented the following: the number of subjects,
the outcome measures used, the type of treatment, the dose reg-
imen used, the nature of the control group, the method of allo-
cation, the extent of blinding, the duration of the treatment, the
method of analysis and the adverse affects.
In trials where the results were not expressed in a form that allowed
extraction of all the necessary data, we approached the investiga-
tors by letter for more information. Nine investigators were ap-
proached, eight responded and six provided data. This procedure
was not followed for updates.
Outcome Measures
The trials reported a wide variety of outcome measures including
joint index, pain score, global assessments and blood parameters.
No consensus exists on the appropriate endpoints to be reported in
psoriatic arthritis clinical trials however a core set of outcome mea-
sures has been developed to measure disease activity for rheuma-
toid arthritis clinical trials at the OMERACT (Outcome Measures
in Rheumatology). These measures (acute phase reactants, disabil-
ity, pain, patient global assessment, physician global assessment,
swollen joint count, tender joint count and radiographic changes
of joints in any trial of 1 year or longer) known as the core set
(Tugwell 1993) have been selected on the basis of validity and we
accepted any or all of these measures for inclusion in the pooled
disease index.
We chose to look at change in individual disease activity measures
where available for each of the agents. Some modification was
necessary for comparison and pooling purposes:
a. Pain scales were all converted to the same scale as a 100mm
visual analogue scale for both continuous and categorical scales.
b. Joint activity scores were all converted to the same scale as a
Ritchie Index (the most common scale used) where possible.
Other component variables did not require any modification.
We also examined a summary measure of treatment effect: the
pooled disease index (Goldsmith 1993). This index weights each
component variable equally allowing them to be combined. We
modified this to allow comparison between agents by dividing by
the number of component variables (which varied between studies)
so that the index generated has a mean of 0 and a standard deviation
(SD) of 1. Thus, unlike the normal disease index, a change in
Disease Index (DI) of 1 unit approximates a 1 SD change in each
of the component variables (if the component variables are highly
correlated).
Data Analysis
As RevMan allows for only one entry for placebo and treatment
arms and data was available for both baseline and follow-up peri-
ods, we calculated N using the formula for the harmonic mean N
= 2N1N2/(N1 + N2)
We calculated the SD by using a weighted formula of individual
SDs
SD squared = [SD1 squared (N1-1) + SD2 squared (N2 -1)]/
(N1+N2-2)
where N1 and N2 are the baseline and follow-up numbers and
SD1 and SD2 are the baseline and follow-up standard deviations.
Where there was only one trial looking at an agent, results were
generated as both disease index and component value listed with
95% confidence intervals (CI). The variance of the change in the
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disease index was calculated by assuming that baseline and follow-
up measurements for both the treatment and placebo arms were
unpaired. This was necessary as data were only available as group
means and standard deviation at baseline and follow-up rather
than individual data. Also, because of dropouts patient numbers
were often not the same in the two groups. This represents a
conservative approach, in terms of type l error, to estimation of the
variance. In crossover trials the treatment-placebo difference was a
paired comparison rather than a comparison of two independent
groups. An additional assumption was that a disease index has an
SD of one unit (from the standardised normal distribution).
When there was more than one trial looking at the same agent a
pooled DI (and pooled component variable where available) were
calculated by the weighted average of the individual disease indices
(or component variable) with the weighting inversely proportional
to the variance of each individual disease index (or component
variable) again listed with 95% CIs. Thus, a study with a larger
sample size will have a disproportionately higher weighting than a
smaller study. We also adapted the conventional chi-squared test
for homogeneity which was applied where there was more than one
trial for an individual agent as well as for placebo versus baseline.
This test is to check the assumption that all trials are samples from
the same population of studies (the central limit theorem) and
thus their 95% confidence limits should all overlap.
R E S U L T S
Description of studies
See characteristics of included studies
Risk of bias in included studies
Each of the trials included in the meta-analysis was assessed for
quality by using a modified version of previously published work
(Wilson 1992) as well as the Allocation Concealment (Schulz
1995). For this purpose “quality” is defined in terms of the mea-
sures taken by the investigators to minimize bias in each trial. The
trials were scored independently of the method of data extraction
and were rated in the range 0-3 on each of the following features:
a) degree to which randomization was truly blind
b) inclusion of data from subjects who subsequently withdrew
from the study (intention to treat)
c) degree to which assessors of outcome were blind to treatment
allocation
d) whether subjects were assessed to determine if they had accu-
rately guessed their treatment status
e) whether an appropriate range of clinical outcome measures had
been used
Scores for the individual quality items were summed for the pur-
poses of analysis. The total possible score was 15 points.
Effects of interventions
A total of twenty randomized controlled trials were identified [see
references]. Complete or near complete data were available on
thirteen trials which included 1022 subjects as randomized. There
was inadequate data to consider toxicity. Randomized controlled
trials were not available for antimalarials, cyclosporin or alkylating
agents.
Data necessary for pooling could not be extracted from papers
by Black (high dose parenteral methotrexate) (Black 1964) , Price
(D-Penicillamine) (Price 1986), Seideman (colchicine) (Seideman
1987), Caperton (Ceftriaxone) (Caperton 1990), Fierlbeck (Inter-
feron) (Fierlbeck 1990) and efamol marine [Veale]. A further trial
of gold versus auranofin was not included as there was no placebo
comparison (Bruckle 1994). Of the included trials the effect of
auranofin was each examined by two trials; colchicine, etretinate,
fumaric acid, IM Gold, azathioprine and oral methotrexate by one
trial and sulfasalazine by six trials. The quality scores varied widely
There was a weak inverse correlation between trial quality and
magnitude of improvement (Spearmans rho=-0.3, p=0.20). How-
ever trial quality was strongly associated with year of publication
(Spearmans rho=0.65, p=0.01).
There were considerable differences in the inclusion and exclusion
criteria of the individual trials. For example one of the trials look-
ing at the efficacy of gold and auranofin excluded patients who
had previously received gold or other suppressive anti-rheumatic
therapy (Palit 1990) while the other accepted patients who had
had prior gold (Carette 1989). Wash out periods between 2 and
3 months were required by five trials (Willkens 1984, Hopkins
1985, Carette 1989, Fraser 1993, Dougados 1995). Similarly trials
varied according to whether they permitted the use of prednisone
during the trial (see references) and one trial permitted patients to
remain on methotrexate (McKendry 1993).
EFFECTS ON OUTCOME
The following table shows the results for individual component
variables from the eleven studies included in the quantitative anal-
ysis
Table 1
sulfasalazine achieved the largest number of statistically significant
results reflecting both the fact that it was the agent studied in the
most subjects as well as being efficacious.
The disease index was statistically significantly improved relative
to placebo in one study of sulfasalazine (Dougados 1995), aza-
thioprine (Levy 1972) and etretinate (Hopkins 1985) and con-
fidence limits just overlapped zero in a further trial of low dose
methotrexate (Willkens 1984). When the pooled indices for in-
dividual agents were examined sulfasalazine (improvement in dis-
ease index 0.38 units (95% CI 0.21-0.54) and azathioprine (im-
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provement in disease index 2.20 units (95% CI 1.06-3.33) and
etretinate (improvement in disease index 0.84 units (95% CI 0.08-
1.59) were statistically better than placebo. However, only one
component variable (Ritchie score) was available for azathioprine
and there was only one small trial of etretinate with a high dropout
rate in the placebo arm suggesting some caution is necessary in
interpreting both of these results. Data for high dose parenteral
methotrexate were unavailable for comparison purposes but it was
clearly much better than placebo (p<0.001). Combinable data
were not available for one trial of colchicine (Seideman 1987) but
an estimate was possible and showed a large improvement in dis-
ease index (3.66 units 95% CI 2.84-4.47). If this was combined
with the included trial a pooled estimate of 1.70 units improve-
ment was obtained (95% CI -2.20-5.60) but there was marked
heterogeneity (p<0.0001) which indicates that marked caution
should be used in the interpretation of this result. All other pooled
indices were homogeneous.
In all the trials the placebo group improved over baseline (pooled
mean improvement 0.39 DI units, 95% CI 0.26-0.52). This im-
provement was also homogeneous (p=0.18).
Table 2 shows a comparison between previously published effect
sizes in rheumatoid arthritis (Felson 1990) and psoriatic arthritis.
The outstanding difference is the placebo group improves three
times as much as the placebo rheumatoid group (p<0.05). Gold
compounds appear less efficacious in psoriatic arthritis but these
differences were not statistically significant.
Table 2
#all results are listed with 95% confidence intervals.
* extracted from (Felson 1990).
D I S C U S S I O N
The study provides the first comprehensive overview of ran-
domized controlled trials of psoriatic arthritis. It demonstrates
published efficacy for sulfasalazine and parenteral high dose
methotrexate and suggestive evidence for azathioprine, etretinate
and low dose methotrexate. Importantly, it shows differences be-
tween rheumatoid arthritis and psoriatic arthritis not only in re-
sponse to treatment but also in the magnitude of improvement
observed in the placebo arm. This latter finding, in particular, has
significant implications for the interpretation of uncontrolled tri-
als in this condition.
There are a number of potential limitations in this review stem-
ming from the methodological shortcomings in the primary tri-
als. The trial sizes are generally small with insufficient statistical
power increasing the likelihood of type II errors. This could affect
the results with low dose methotrexate and perhaps colchicine.
Secondly, subgroup analyses of results were not possible with this
meta analysis as the patient groups had been poorly characterized.
There is some limited support in the literature for the hypothe-
sis that different subtypes respond differently to treatment [Price
1984]. This may indicate that bias could be introduced by mald-
istribution of arthritis subtypes between treatment and placebo
arms. Thirdly these studies are of short duration with a mean du-
ration of six months and these results cannot be extrapolated be-
yond this period. Finally, it would be possible to criticize the out-
come measure we chose for this review. In this overview, we lim-
ited the component variables to those described at OMERACT
1 (Tugwell 1993). We were careful to equally weigh all variables
and ensure that the final disease index had a variance of 1 for each
agent to allow direct comparison. Ideally each disease index should
have had the same number of component variables but that was
not possible in this case. This would not bias our findings unless
one component variable was much more sensitive to change than
others which, intuitively, appears unlikely in this case as all the
variables are correlated with each other. This may not apply in
the case of azathioprine where only one variable was available for
pooling with a highly significant result that was an outlier in terms
of effect size (in comparison to other agents) and may well have
been diluted with further variables or an increase in sample size.
We would still contend, however, that this measure is among the
best available and has been well validated and widely accepted in
rheumatoid arthritis.
The use of one outcome measure gives a global effect estimate
and minimizes the risk of type I error by eradicating the need for
multiple comparisons with the different possible outcome mea-
sures. The results obtained from the individual component vari-
able analysis reflect the greater variation that would be expected
when compared to a global or summary effect estimate. However,
in general, component results were in the same direction as the
global estimate
With regard to the trials with incomplete data only the trial of
high dose methotrexate showed a marked improvement in the
treatment group as compared to the placebo group (Black 1964).
However, as was shown in this trial, this dose would be too toxic
for use in current practice. The other studies showed effect sizes
that appeared similar in magnitude to Auranofin and IM Gold
(Price 1986, Caperton 1990, Fierlbeck 1990).
The uniform improvement seen in the placebo arm indicates that
uncontrolled trials should not be used to guide management de-
cisions in psoriatic arthritis. The improvement may be due to a
number of possible factors but it seems most likely that it reflects
the natural history of this condition. The interpretation of uncon-
trolled studies in this condition will be extremely difficult as virtu-
ally all would be expected to show a positive effect which may be
erroneously attributed to the treatment. Our calculations suggest
that further trials will require 85 subjects per treatment arm to
determine a 0.5 unit improvement in disease index for treatment
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over placebo (with 90% power and 5% significance level). Ob-
viously, inter-drug comparisons will require much larger sample
sizes. This indicates that future therapeutic trials for this condition
will need to be multicentre in design.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The results of uncontrolled trials are likely to be misleading in
psoriatic arthritis. At present, parenteral high dose methotrexate,
sulfasalazine and possibly azathioprine and etretinate are the only
agents which are statistically better than placebo for the treatment
of this condition. However, the magnitude of the effect seen with
low dose methotrexate, and perhaps colchicine suggests that they
may also be effective.
Implications for research
Further multicentre clinical trials are required to establish the ef-
ficacy of azathioprine, etretinate, low dose oral methotrexate and
colchicine.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Carette 1989
Methods Random allocation (computer generated random numbers block design)
Method of concealment not stated
Participants Psoriasis, arthritis, partial response to NSAIDs, >3 joints, could be seropositive
Multicentre design (USA and Canada)
N=238
Mean age 44, median duration of arthritis 5 years
Interventions Auranofin 3mg/day versus identical placebo
Outcomes All Omeract 1 outcomes
24 weeks duration
Notes Only three outcomes could be included even after communication with authors due to
nature of outcomes (some categorical which meant means and SDs could not be calculated)
21% withdrew
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk A - Adequate
Clegg 1996
Methods Random allocation (exact method and concealment not stated)
Participants Psoriasis, active arthritis, failed NSAIDs, steroids not allowed, N=221
Interventions Salazopyrin 2g/ day versus identical placebo
Outcomes All Omeract 1 outcomes , 36 weeks duration
Notes Only three outcomes could be included due to method of reporting
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
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Combe 1996
Methods Random allocation (exact method and concealment not stated)
Participants Psoriatic arthritis (definition not stated)
N=120
Interventions Salazopyrin 2g/day versus placebo




3 variables available for inclusion after discussion with authors
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
Dougados 1995
Methods Random allocation (computer generated numbers)
metrologist blinded to treatment allocation
Participants Multicentre spondyloarthropathy trial
N=136 (psoriatic arthritis only)
Interventions Salazopyrin 2g/day versus identical placebo
Outcomes All Omeract 1 outcomes
Duration 24 weeks
Notes 3 variables included in analysis after discussion with authors
Intention-to-treat analysis
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk A - Adequate
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Farr 1990
Methods Random allocation (exact method and concealment not stated)
Participants Seronegative arthritis associated with psoriasis unresponsive to NSAIDs alone
Rheumatology research clinic in Birmingham, UK
N=30
mean age 46, equal male female ratio, mean duration of arthritis 7 years
Interventions Salazopyrin 2g/day versus placebo
intra-articular steroids only permitted
duration 24 weeks
Outcomes Multiple measures of disease activity (EMS, painful joint score, pain score (VAS), global
assessment (subjective), grip strength, articular index, laboratory measures)
Notes Data for pain, articular index and ESR only were available for inclusion after communica-
tion with authors
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
Fraser 1993
Methods Random allocation (method not stated)
Metrologist blind to treatment allocation
Participants Psoriasis, seronegative asymmetric polyarthritis, no spinal involvement
Hospital and university clinics, Leeds and Glasgow, UK
N=39
Interventions Salazopyrin 2g/day versus identical placebo
Outcomes Pain (VAS), Morning stiffness, Ritchie index, grip strength, laboratory measures
duration 24 weeks
Notes 7% dropout rate
3 variables available for inclusion in analysis
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
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Gupta 1995
Methods Random allocation (method not stated)
Participants Active psoriatic arthritis, NSAIDS permitted, steroids not permitted. N=24
Interventions Salazopyrin 3g/day versus placebo
Outcomes All Omeract 1 measures
Notes Small sample size
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
Hopkins 1985
Methods Random allocation (method and concealment not stated)
Participants Psoriasis, arthritis >3 joints, seronegative
Setting: hospital clinics, UK
N=40
Interventions Etretinate 0.5 mg/kg/day plus placebo versus ibuprofen 400mg tds plus placebo
Outcomes Articular index, grip strength, joint size, laboratory tests
Duration 24 weeks
Notes Substantial loss to follow-up in ibuprofen group (8/20 completed second assessment)
Data on three outcome variables included
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
Levy 1972
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Levy 1972 (Continued)
Interventions Azathioprine 3mg/kg/day versus placebo
Outcomes Tender joint score, Morning stiffness
duration 26 weeks
Notes Small study only reported in abstract form
Only one variables included in analysis
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
McKendry 1993
Methods Random allocation by computer code (exact method of concealment not stated)
Crossover design (1 week washout period)
Participants Arthritis and psoriasis, age >18, >3 joints, seronegative, methotrexate and oral steroids
permitted
University of Ottawa rheumatic disease unit
N=25
Interventions Colchicine 0.6-1.8 mg/day versus placebo
Outcomes Pain, morning stiffness, grip strength, Lansbury joint count, swollen joints, joint circum-
ference, laboratory measures, global assessment
Duration 23 weeks
Notes Data only adequate for inclusion of 2 variables
No loss to follow-up
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk A - Adequate
Palit 1990
Methods Random allocation (method not stated)
Metrologist blinded to treatment
Participants Active symptomatic psoriatic arthritis >1 year duration
Steroids not permitted
N=82
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Palit 1990 (Continued)
Interventions Auranofin 3mg bd versus IM gold thiomalate versus placebo tablet only
Outcomes Ritchie index, pain (VAS), grip strength, ESR
24 weeks duration
Notes 3 variables included after discussion with authors
38% dropout rate
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
Peeters 1992
Methods Random allocation (exact method and concealment not stated)
Participants Psoriatic arthritis
Mean age 40, mean duration 6 years
N=27
Interventions Fumaric acid 120mg/day versus placebo tablet
Outcomes Morning stiffness, pain score, global assessment, grip strength, joint index, laboratory
measures
16 weeks duration
Notes Four variables included in analysis
7% dropouts.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
Willkens 1984
Methods Random allocation (exact method and concealment not stated)
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Willkens 1984 (Continued)
Interventions Oral methotrexate 7.5-15 mg/wk versus identical placebo
Outcomes Tender joint count, joint swelling, physician assessment, grip strength, laboratory measures
duration 12 weeks
Notes 4 variables were included after discussion with the authors
11% dropout rate
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Black 1964 Data not available to allow comparison with other studies.
Bruckle 1994 No placebo arm.
Caperton 1990 Different study group (Lyme positive subjects with psoriatic arthritis). Authors not contacted
Fierlbeck 1990 Data not available to allow comparison with included studies. Authors contacted but failed to respond
Price 1986 Data not available to allow comparison with included studies. Authors were contacted but data was lost
Seideman 1987 Data not available in format to include in this overview
Veale 1994
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D A T A A N D A N A L Y S E S
Comparison 1. Treatment versus placebo




participants Statistical method Effect size
1 Pooled disease index 13 Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 Salazopyrin 6 564 Mean Difference (IV, Fixed, 95% CI) 0.38 [0.21, 0.54]
1.2 Etretinate 1 29 Mean Difference (IV, Fixed, 95% CI) 0.84 [0.09, 1.59]
1.3 IMI Gold 1 39 Mean Difference (IV, Fixed, 95% CI) 0.23 [-0.40, 0.86]
1.4 Fumaric acid 1 26 Mean Difference (IV, Fixed, 95% CI) 0.41 [-0.36, 1.18]
1.5 Azathioprine 1 12 Mean Difference (IV, Fixed, 95% CI) 2.2 [1.07, 3.33]
1.6 Colchicine 1 50 Mean Difference (IV, Fixed, 95% CI) -0.30 [-0.85, 0.25]
1.7 Methotrexate 1 37 Mean Difference (IV, Fixed, 95% CI) 0.65 [-.00, 1.30]
1.8 Auranofin 2 230 Mean Difference (IV, Fixed, 95% CI) 0.13 [-0.13, 0.39]
2 Pain (VAS) 9 Mean Difference (IV, Fixed, 95% CI) Subtotals only
2.1 Salazopyrin 4 320 Mean Difference (IV, Fixed, 95% CI) -9.50 [-15.04, -3.96]
2.2 Etretinate 1 29 Mean Difference (IV, Fixed, 95% CI) -5.6 [-23.15, 11.95]
2.3 IMI Gold 1 39 Mean Difference (IV, Fixed, 95% CI) 5.30 [-9.17, 19.77]
2.4 Fumaric acid 1 26 Mean Difference (IV, Fixed, 95% CI) -16.64 [-40.61, 7.
33]
2.5 Colchicine 1 30 Mean Difference (IV, Fixed, 95% CI) 14.3 [-2.31, 30.91]
2.6 Auranofin 2 230 Mean Difference (IV, Fixed, 95% CI) -2.99 [-3.23, -2.76]
3 ESR (mm/hr) 7 Mean Difference (IV, Fixed, 95% CI) Subtotals only
3.1 Salazopyrin 4 405 Mean Difference (IV, Fixed, 95% CI) -7.52 [-10.74, -4.29]
3.2 Etretinate 1 29 Mean Difference (IV, Fixed, 95% CI) -9.00 [-15.23, -6.77]
3.3 IMI gold 1 39 Mean Difference (IV, Fixed, 95% CI) -7.10 [-22.07, 7.87]
3.4 Fumaric acid 1 26 Mean Difference (IV, Fixed, 95% CI) -15.0 [-27.72, -2.28]
3.5 Auranofin 1 42 Mean Difference (IV, Fixed, 95% CI) 0.10 [-13.04, 13.24]
4 Tender joint score (Ritchie
Index)
8 Mean Difference (IV, Fixed, 95% CI) Subtotals only
4.1 Salazopyrin 3 361 Mean Difference (IV, Fixed, 95% CI) -1.20 [-3.09, 0.68]
4.2 Etretinate 1 29 Mean Difference (IV, Fixed, 95% CI) 0.30 [-6.66, 7.26]
4.3 IMI Gold 1 39 Mean Difference (IV, Fixed, 95% CI) -6.60 [-11.92, -1.28]
4.4 Azathioprine 1 12 Mean Difference (IV, Fixed, 95% CI) -12.0 [-17.56, -6.44]
4.5 Auranofin 2 230 Mean Difference (IV, Fixed, 95% CI) -0.67 [-1.81, 0.47]
4.6 Methotrexate 1 37 Mean Difference (IV, Fixed, 95% CI) 1.01 [-9.47, 11.49]
5 Swollen joint score 6 Mean Difference (IV, Fixed, 95% CI) Subtotals only
5.1 Colchicine 1 30 Mean Difference (IV, Fixed, 95% CI) -0.10 [-2.25, 2.05]
5.2 Fumaric acid 1 26 Mean Difference (IV, Fixed, 95% CI) 0.0 [-3.51, 3.51]
5.3 Auranofin 1 188 Mean Difference (IV, Fixed, 95% CI) -0.40 [-0.74, -0.06]
5.4 Methotrexate 1 37 Mean Difference (IV, Fixed, 95% CI) -0.20 [-7.32, 6.92]
5.5 Salazopyrine 2 244 Mean Difference (IV, Fixed, 95% CI) -0.15 [-3.09, 2.79]
6 Patient global assessment 4 Mean Difference (IV, Fixed, 95% CI) Subtotals only
6.1 Salazopyrin 2 159 Mean Difference (IV, Fixed, 95% CI) -0.55 [-0.79, -0.31]
6.2 Methotrexate 1 37 Mean Difference (IV, Fixed, 95% CI) -0.41 [-0.74, -0.08]
6.3 Fumaric acid 1 26 Mean Difference (IV, Fixed, 95% CI) -0.40 [-1.23, 0.43]
7 Physician global assessment 3 Mean Difference (IV, Fixed, 95% CI) Subtotals only
7.1 Salazopyrin 2 159 Mean Difference (IV, Fixed, 95% CI) -0.27 [-0.48, -0.05]
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7.2 Methotrexate 1 37 Mean Difference (IV, Fixed, 95% CI) -0.88 [-1.22, -0.54]
Comparison 2. Placebo follow-up versus baseline




participants Statistical method Effect size
1 Pooled disease index Other data No numeric data
Analysis 1.1. Comparison 1 Treatment versus placebo, Outcome 1 Pooled disease index.
Review: Interventions for treating psoriatic arthritis
Comparison: 1 Treatment versus placebo
Outcome: 1 Pooled disease index





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Salazopyrin
Clegg 1996 109 0.5 (1) 112 0.31 (1) 39.4 % 0.19 [ -0.07, 0.45 ]
Combe 1996 53 0.77 (1) 64 0.4 (1) 20.7 % 0.37 [ 0.01, 0.73 ]
Dougados 1995 70 1.31 (1) 66 0.61 (1) 24.2 % 0.70 [ 0.36, 1.04 ]
Farr 1990 15 1.56 (1) 15 1.12 (1) 5.3 % 0.44 [ -0.28, 1.16 ]
Fraser 1993 17 1.02 (1) 20 1.24 (1) 6.5 % -0.22 [ -0.87, 0.43 ]
Gupta 1995 9 1.2 (1) 14 0 (1) 3.9 % 1.20 [ 0.36, 2.04 ]
Subtotal (95% CI) 273 291 100.0 % 0.38 [ 0.21, 0.54 ]
Heterogeneity: Chi2 = 12.49, df = 5 (P = 0.03); I2 =60%
Test for overall effect: Z = 4.46 (P < 0.00001)
2 Etretinate
Hopkins 1985 18 1.19 (1) 11 0.35 (1) 100.0 % 0.84 [ 0.09, 1.59 ]
Subtotal (95% CI) 18 11 100.0 % 0.84 [ 0.09, 1.59 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.19 (P = 0.028)
3 IMI Gold
Palit 1990 21 0.67 (1) 18 0.44 (1) 100.0 % 0.23 [ -0.40, 0.86 ]
Subtotal (95% CI) 21 18 100.0 % 0.23 [ -0.40, 0.86 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
4 Fumaric acid
Peeters 1992 12 0.66 (1) 14 0.25 (1) 100.0 % 0.41 [ -0.36, 1.18 ]
Subtotal (95% CI) 12 14 100.0 % 0.41 [ -0.36, 1.18 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.04 (P = 0.30)
5 Azathioprine
Levy 1972 6 2.2 (1) 6 0 (1) 100.0 % 2.20 [ 1.07, 3.33 ]
Subtotal (95% CI) 6 6 100.0 % 2.20 [ 1.07, 3.33 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.81 (P = 0.00014)
6 Colchicine
McKendry 1993 25 0.09 (1) 25 0.39 (1) 100.0 % -0.30 [ -0.85, 0.25 ]
Subtotal (95% CI) 25 25 100.0 % -0.30 [ -0.85, 0.25 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.06 (P = 0.29)
7 Methotrexate
Willkens 1984 16 0.78 (1) 21 0.13 (1) 100.0 % 0.65 [ 0.00, 1.30 ]
Subtotal (95% CI) 16 21 100.0 % 0.65 [ 0.00, 1.30 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.96 (P = 0.050)
8 Auranofin
Carette 1989 93 0.46 (1) 95 0.23 (1) 82.0 % 0.23 [ -0.06, 0.52 ]
Palit 1990 24 0.1 (1) 18 0.44 (1) 18.0 % -0.34 [ -0.95, 0.27 ]
Subtotal (95% CI) 117 113 100.0 % 0.13 [ -0.13, 0.39 ]
Heterogeneity: Chi2 = 2.74, df = 1 (P = 0.10); I2 =64%
Test for overall effect: Z = 0.97 (P = 0.33)
Test for subgroup differences: Chi2 = 20.94, df = 7 (P = 0.00), I2 =67%
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Analysis 1.2. Comparison 1 Treatment versus placebo, Outcome 2 Pain (VAS).
Review: Interventions for treating psoriatic arthritis
Comparison: 1 Treatment versus placebo
Outcome: 2 Pain (VAS)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Salazopyrin
Combe 1996 53 -22.9 (27.7) 64 -12.6 (30.2) 27.8 % -10.30 [ -20.81, 0.21 ]
Dougados 1995 70 -21.5 (25.6) 66 -7.06 (22) 47.9 % -14.44 [ -22.45, -6.43 ]
Farr 1990 15 -43.1 (26) 15 -35.8 (21) 10.7 % -7.30 [ -24.21, 9.61 ]
Fraser 1993 17 -22.5 (18.9) 20 -30.4 (27.6) 13.5 % 7.90 [ -7.17, 22.97 ]
Subtotal (95% CI) 155 165 100.0 % -9.50 [ -15.04, -3.96 ]
Heterogeneity: Chi2 = 6.67, df = 3 (P = 0.08); I2 =55%
Test for overall effect: Z = 3.36 (P = 0.00078)
2 Etretinate
Hopkins 1985 18 -2.6 (28.2) 11 3 (19.9) 100.0 % -5.60 [ -23.15, 11.95 ]
Subtotal (95% CI) 18 11 100.0 % -5.60 [ -23.15, 11.95 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
3 IMI Gold
Palit 1990 21 -21.2 (24.3) 18 -26.5 (21.8) 100.0 % 5.30 [ -9.17, 19.77 ]
Subtotal (95% CI) 21 18 100.0 % 5.30 [ -9.17, 19.77 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
4 Fumaric acid
Peeters 1992 12 -26.64 (33) 14 -10 (28.7) 100.0 % -16.64 [ -40.61, 7.33 ]
Subtotal (95% CI) 12 14 100.0 % -16.64 [ -40.61, 7.33 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.36 (P = 0.17)
5 Colchicine
McKendry 1993 15 -1.2 (23.5) 15 -15.5 (22.9) 100.0 % 14.30 [ -2.31, 30.91 ]
Subtotal (95% CI) 15 15 100.0 % 14.30 [ -2.31, 30.91 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.69 (P = 0.091)
6 Auranofin
Carette 1989 93 -5 (0.75) 95 -2 (0.9) 100.0 % -3.00 [ -3.24, -2.76 ]
Palit 1990 24 -4.6 (23.1) 18 -26.5 (21.8) 0.0 % 21.90 [ 8.23, 35.57 ]
Subtotal (95% CI) 117 113 100.0 % -2.99 [ -3.23, -2.76 ]
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Heterogeneity: Chi2 = 12.74, df = 1 (P = 0.00036); I2 =92%
Test for overall effect: Z = 24.79 (P < 0.00001)
Test for subgroup differences: Chi2 = 12.05, df = 5 (P = 0.03), I2 =58%
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Analysis 1.3. Comparison 1 Treatment versus placebo, Outcome 3 ESR (mm/hr).
Review: Interventions for treating psoriatic arthritis
Comparison: 1 Treatment versus placebo
Outcome: 3 ESR (mm/hr)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Salazopyrin
Clegg 1996 109 -6.4 (14.9) 112 1.1 (15) 66.9 % -7.50 [ -11.44, -3.56 ]
Combe 1996 53 -10.7 (21.7) 64 -4.1 (17.4) 19.9 % -6.60 [ -13.83, 0.63 ]
Farr 1990 15 -23.1 (17) 15 -16.4 (14) 8.4 % -6.70 [ -17.84, 4.44 ]
Fraser 1993 17 -17 (20.4) 20 -4 (25.2) 4.8 % -13.00 [ -27.70, 1.70 ]
Subtotal (95% CI) 194 211 100.0 % -7.52 [ -10.74, -4.29 ]
Heterogeneity: Chi2 = 0.62, df = 3 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 4.57 (P < 0.00001)
2 Etretinate
Hopkins 1985 11 -14 (6) 18 -3 (5) 100.0 % -11.00 [ -15.23, -6.77 ]
Subtotal (95% CI) 11 18 100.0 % -11.00 [ -15.23, -6.77 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.09 (P < 0.00001)
3 IMI gold
Palit 1990 21 -9.3 (22.8) 18 -2.2 (24.6) 100.0 % -7.10 [ -22.07, 7.87 ]
Subtotal (95% CI) 21 18 100.0 % -7.10 [ -22.07, 7.87 ]
Heterogeneity: not applicable
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Test for overall effect: Z = 0.93 (P = 0.35)
4 Fumaric acid
Peeters 1992 12 -20 (16.9) 14 -5 (16) 100.0 % -15.00 [ -27.72, -2.28 ]
Subtotal (95% CI) 12 14 100.0 % -15.00 [ -27.72, -2.28 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.31 (P = 0.021)
5 Auranofin
Palit 1990 24 -2.1 (16.5) 18 -2.2 (24.6) 100.0 % 0.10 [ -13.04, 13.24 ]
Subtotal (95% CI) 24 18 100.0 % 0.10 [ -13.04, 13.24 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.01 (P = 0.99)
Test for subgroup differences: Chi2 = 4.36, df = 4 (P = 0.36), I2 =8%
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Analysis 1.4. Comparison 1 Treatment versus placebo, Outcome 4 Tender joint score (Ritchie Index).
Review: Interventions for treating psoriatic arthritis
Comparison: 1 Treatment versus placebo
Outcome: 4 Tender joint score (Ritchie Index)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Salazopyrin
Clegg 1996 109 -10.3 (22.4) 112 -7.8 (19.1) 11.8 % -2.50 [ -8.00, 3.00 ]
Combe 1996 53 -4.4 (4.5) 64 -3.5 (6.6) 87.4 % -0.90 [ -2.92, 1.12 ]
Gupta 1995 9 -13 (21.77) 14 2 (29.1) 0.8 % -15.00 [ -35.85, 5.85 ]
Subtotal (95% CI) 171 190 100.0 % -1.20 [ -3.09, 0.68 ]
Heterogeneity: Chi2 = 1.98, df = 2 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 1.25 (P = 0.21)
2 Etretinate
Hopkins 1985 18 -2.1 (8.07) 11 -2.4 (9.95) 100.0 % 0.30 [ -6.66, 7.26 ]
Subtotal (95% CI) 18 11 100.0 % 0.30 [ -6.66, 7.26 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.08 (P = 0.93)
3 IMI Gold
Palit 1990 21 -8.9 (9.7) 18 -2.3 (7.2) 100.0 % -6.60 [ -11.92, -1.28 ]
Subtotal (95% CI) 21 18 100.0 % -6.60 [ -11.92, -1.28 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.43 (P = 0.015)
4 Azathioprine
Levy 1972 6 -12 (3.5) 6 0 (6) 100.0 % -12.00 [ -17.56, -6.44 ]
Subtotal (95% CI) 6 6 100.0 % -12.00 [ -17.56, -6.44 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.23 (P = 0.000023)
5 Auranofin
Carette 1989 93 -12 (4.2) 95 -11.1 (4.05) 93.0 % -0.90 [ -2.08, 0.28 ]
Palit 1990 24 0.1 (6.8) 18 -2.3 (7.2) 7.0 % 2.40 [ -1.90, 6.70 ]
Subtotal (95% CI) 117 113 100.0 % -0.67 [ -1.81, 0.47 ]
Heterogeneity: Chi2 = 2.11, df = 1 (P = 0.15); I2 =53%
Test for overall effect: Z = 1.15 (P = 0.25)
6 Methotrexate
Willkens 1984 16 -4.15 (15.4) 21 -5.16 (17) 100.0 % 1.01 [ -9.47, 11.49 ]
Subtotal (95% CI) 16 21 100.0 % 1.01 [ -9.47, 11.49 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.19 (P = 0.85)
Test for subgroup differences: Chi2 = 19.63, df = 5 (P = 0.00), I2 =75%
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Analysis 1.5. Comparison 1 Treatment versus placebo, Outcome 5 Swollen joint score.
Review: Interventions for treating psoriatic arthritis
Comparison: 1 Treatment versus placebo
Outcome: 5 Swollen joint score





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Colchicine
McKendry 1993 15 -0.3 (2.87) 15 -0.2 (3.13) 100.0 % -0.10 [ -2.25, 2.05 ]
Subtotal (95% CI) 15 15 100.0 % -0.10 [ -2.25, 2.05 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.09 (P = 0.93)
2 Fumaric acid
Peeters 1992 12 -0.1 (5.75) 14 -0.1 (2.5) 100.0 % 0.0 [ -3.51, 3.51 ]
Subtotal (95% CI) 12 14 100.0 % 0.0 [ -3.51, 3.51 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
3 Auranofin
Carette 1989 93 -2.4 (1.1) 95 -2 (1.3) 100.0 % -0.40 [ -0.74, -0.06 ]
Subtotal (95% CI) 93 95 100.0 % -0.40 [ -0.74, -0.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.28 (P = 0.023)
4 Methotrexate
Willkens 1984 16 -2.57 (10.5) 21 -2.37 (11.5) 100.0 % -0.20 [ -7.32, 6.92 ]
Subtotal (95% CI) 16 21 100.0 % -0.20 [ -7.32, 6.92 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.96)
5 Salazopyrine
Clegg 1996 109 -7.8 (12.8) 112 -8 (13.7) 70.8 % 0.20 [ -3.29, 3.69 ]
Gupta 1995 9 -7 (7.54) 14 -6 (4.4) 29.2 % -1.00 [ -6.44, 4.44 ]
Subtotal (95% CI) 118 126 100.0 % -0.15 [ -3.09, 2.79 ]
Heterogeneity: Chi2 = 0.13, df = 1 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 0.10 (P = 0.92)
Test for subgroup differences: Chi2 = 0.15, df = 4 (P = 1.00), I2 =0.0%
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Analysis 1.6. Comparison 1 Treatment versus placebo, Outcome 6 Patient global assessment.
Review: Interventions for treating psoriatic arthritis
Comparison: 1 Treatment versus placebo
Outcome: 6 Patient global assessment





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Salazopyrin
Dougados 1995 70 -0.81 (0.8) 66 -0.32 (0.7) 91.9 % -0.49 [ -0.74, -0.24 ]
Gupta 1995 9 -0.9 (0.99) 14 0.3 (1.06) 8.1 % -1.20 [ -2.05, -0.35 ]
Subtotal (95% CI) 79 80 100.0 % -0.55 [ -0.79, -0.31 ]
Heterogeneity: Chi2 = 2.45, df = 1 (P = 0.12); I2 =59%
Test for overall effect: Z = 4.43 (P < 0.00001)
2 Methotrexate
Willkens 1984 16 -0.57 (0.26) 21 -0.16 (0.72) 100.0 % -0.41 [ -0.74, -0.08 ]
Subtotal (95% CI) 16 21 100.0 % -0.41 [ -0.74, -0.08 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.41 (P = 0.016)
3 Fumaric acid
Peeters 1992 12 -0.6 (1.14) 14 -0.2 (1) 100.0 % -0.40 [ -1.23, 0.43 ]
Subtotal (95% CI) 12 14 100.0 % -0.40 [ -1.23, 0.43 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.94 (P = 0.35)
Test for subgroup differences: Chi2 = 0.48, df = 2 (P = 0.79), I2 =0.0%
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Analysis 1.7. Comparison 1 Treatment versus placebo, Outcome 7 Physician global assessment.
Review: Interventions for treating psoriatic arthritis
Comparison: 1 Treatment versus placebo
Outcome: 7 Physician global assessment





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Salazopyrin
Dougados 1995 70 -0.64 (0.66) 66 -0.42 (0.65) 96.2 % -0.22 [ -0.44, 0.00 ]
Gupta 1995 9 -1.2 (0.81) 14 0.3 (1.85) 3.8 % -1.50 [ -2.60, -0.40 ]
Subtotal (95% CI) 79 80 100.0 % -0.27 [ -0.48, -0.05 ]
Heterogeneity: Chi2 = 4.97, df = 1 (P = 0.03); I2 =80%
Test for overall effect: Z = 2.44 (P = 0.015)
2 Methotrexate
Willkens 1984 16 -0.72 (0.45) 21 0.16 (0.62) 100.0 % -0.88 [ -1.22, -0.54 ]
Subtotal (95% CI) 16 21 100.0 % -0.88 [ -1.22, -0.54 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.00 (P < 0.00001)
Test for subgroup differences: Chi2 = 8.66, df = 1 (P = 0.00), I2 =88%
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Analysis 2.1. Comparison 2 Placebo follow-up versus baseline, Outcome 1 Pooled disease index.
Pooled disease index
Study
Carette 1989 Improvement 0.44 (95%CI -0.22 - 1.10)
Clegg 1996 Improvement 0.31 (95% CI 0.12-0.50 )
Combe 1996 Improvement 0.40 (95%CI 0.04 - 0.76)
Dougados 1995 Improvement 0.61 (95%CI 0.27 - 0.95 )
Farr 1990 Improvement 1.12 (95%CI 0.38 - 1.86)
Fraser 1993 Improvement 1.24 (95%CI 0.44 - 2.04
Gupta 1995 Improvement 0.00 (95% CI -0.52- 0.52 )
Hopkins 1985 Improvement 0.35 (95%CI -0.49 - 1.19)
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Pooled disease index (Continued)
Levy 1972 Improvement -0.09 (95%CI -1.25- 1.07)
McKendry 1993 Improvement 0.39 (95%CI -0.35- 1.13)
Palit 1990 Improvement 0.44 (95%CI -0.22 - 1.10)
Peeters 1992 Improvement 0.25 (95%CI -0.51 - 1.01)
Willkens 1984 Improvement 0.13 (95%CI -0.49- 0.75)
A D D I T I O N A L T A B L E S
Table 1. Component variables achieving statistical significance with different agents
Variables Agent
Pain Salazopyrin, Auranofin
ESR Salazopyrin, Etretinate, Fumaric Acid
Tender Joint Count IMI Gold, Azathioprine
Swollen Joint Count Auranofin
Patient Global Assessment Salazopyrin, Methotrexate
Physician Global Assessment Salazopyrin, Methotrexate
Table 2. Psoriatic arthritis versus Rheumatoid arthritis
placebo vs baseline 0.39 (+0.26-+0.52) 0.15 (+0.11-+0.19)
treatment vs placebo
Auranofin 0.12(-0.13-+0.38) 0.30 (+0.06-+0.54)
IM Gold 0.23 (-0.13-+0.38) 0.56 (+0.11-+1.01
Methotrexate 0.65 (-0.00-+1.30) 0.58 (+0.10-+1.06)
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Table 2. Psoriatic arthritis versus Rheumatoid arthritis (Continued)
Salazopyrin 0.38 (+0.21-+0.54) 0.60 (+0.18-+1.02)
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